Heterotopic ossification after hip arthroplasty: a randomized double-blind multicenter study tenoxicam in 147 hips

Acta Orthop Scand. 1996 Feb;67(1):29-32. doi: 10.3109/17453679608995604.


147 patients due to have a cemented total hip arthroplasty were randomized to 4 groups. They received either tenoxicam 20 mg or 40 mg, or placebo, for 5 days or morphine on the day of operation and placebo for 4 days. During the first 5 days 14 patients were excluded. The patients were followed for 1 year, during which another 10 patients were excluded. At follow-up, significantly fewer patients had heterotopic ossifications in the tenoxicam groups than in the placebo and morphine groups. There was no significant difference between the 2 tenoxicam-treated groups, and we therefore conclude that tenoxicam 20 mg for 5 days postoperatively can reduce heterotopic ossification after cemented total hip arthroplasty.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Double-Blind Method
  • Hip Prosthesis*
  • Humans
  • Ossification, Heterotopic / prevention & control*
  • Piroxicam / analogs & derivatives*
  • Piroxicam / therapeutic use
  • Postoperative Complications / prevention & control*
  • Treatment Outcome


  • Anti-Inflammatory Agents, Non-Steroidal
  • Piroxicam
  • tenoxicam